Lannett Reports Insulin Glargine Trial Success
Ready To Present Trial Design For Lantus Rival To FDA
• By Akriti Seth
Lannett has announced positive results from a Phase I trial for biosimilar insulin glargine developed with HEC • Source: Shutterstock 
